US 10,406,250 B2 · Suicide contrast agents targeting HIV reservoirs for theranostic eradication

Abstract

We have developed a model system of HIV reservoirs in neural cells by generating chimeric phosphorothioate-modified oligodeoxynucleotides (sODN) that specifically interact with neural cell DNA or RNA, and that further comprise a sequence of the HIV genome. In particular, we have conjugated the chimera sODN to a delivery vehicle (e.g. a superparamagnetic iron oxide nanoparticle (SPIO)) and have demonstrated specific delivery to neural cells, in vitro and in vivo. These model systems can be used to screen for agents that specifically target latent viral infection. In particular, using the model system, we have developed suicide MRI contrast agents that can be used to reduce the number of neural cells which harbor the virus, also provided herein. Our model system is translatable to other latent viruses as well.

Claims14

Dependent claims

A magnetic resonance imaging (MRI) agent for detecting or killing an HIV-infected cell, the agent comprising a T1 or a T2 contrast agent linked to a single stranded phosphorothioate-modified oligodeoxynucleotide (sODN) that includes a nucleotide sequence that binds specifically to an HIV nucleic acid sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO:

51, SEQ ID NO:
52, SEQ ID NO:
53, SEQ ID NO:
54, SEQ ID NO:
55, SEQ ID NO:
56, SEQ ID NO:
57, SEQ ID NO:
9, SEQ ID NO:
10, SEQ ID NO:
11, SEQ ID NO:
12, SEQ ID NO:
13, SEQ ID NO:
14, and SEQ ID NO:
15.

11 more elements

Dependencies are inferred from the claim text.

Suicide contrast agents targeting HIV reservoirs for theranostic eradication

Life of this patent

Suicide contrast agents targeting HIV reservoirs for theranostic eradication

Life of this patent

Abstract

Claims14